Solid Biosciences has shared positive clinical data for the first three patients in its Inspire Duchenne clinical trial. They have been dosed with Solid’s next generation gene therapy, known as SGT-003.
Biopsy data at day 90 showed average microdystophin expression of 110%. There were also key improvements in markers related to muscle health, and encouraging early signs of potential benefit to the heart.
Solid is continuing its enrolment of patients. Inspire Duchenne has six active trial sites across the US and Canada and will soon be expanding to the UK and Italy, aiming to dose 20 patients by the fourth quarter of 2025. The company also plans to request a meeting with the FDA to discuss the potential for accelerated approval pathway for SGT-003 later this year.
Click here to read Solid’s letter to the Duchenne community about the latest data.
DRF is proud to have been an early funder of Solid Biosciences’ research. Click here to learn more.